Complement Therapeutics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
84 Wood Ln, London, Greater London, W12 ...Website
www.complementtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Complement Therapeutics
Complement Therapeutics is a biotechnology company focused on developing innovative treatments based on insights from the Complement System, particularly for age-related macular degeneration and other complement-related diseases. The company leverages its world-leading expertise and patented research to create novel therapeutic approaches, including AAV gene therapies and protein-based treatments. Their lead asset, CTx001, is in pre-clinical development for Geographic Atrophy, addressing a significant unmet clinical need. Complement Therapeutics aims to transform the lives of patients suffering from complement-mediated diseases through its advanced research and development platforms.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Complement Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Complement Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Complement Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if Complement Therapeutics is spiking on competitors!
Click to see if Complement Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Complement Therapeutics
Earning: See what the market has to say on Complement Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Complement Therapeutics has new funding data
Complement Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Complement Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Complement Therapeutics
Compare insights from companies similar to Complement Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Complement Therapeutics
<$5M
1-10
Private
$84.7M
2020
N/A
Company Profile Activity
Activity Insights
Complement Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Complement Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Complement Therapeutics.
Complement Therapeutics financials insights
Gather financial insights about Complement Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Angel/Seed
$5.7M
2023
Series A
$79M
Complement Therapeutics Tech Stack
A closer look at the technologies used by Complement Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Complement Therapeutics News & Media
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system CTx001 has previously received FDA IND clearance...Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and preliminary efficacy of CTx001 as a potential one-time treatment for GA Opti-GAIN builds on...Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer
MUNICH, Aug. 3, 2023 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately. Dr....Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases
Round led by Gimv, a Belgian based private equity and venture capital firm Round comes just 1 year after raising €5 million seed funding in February 2022 Company aims to transform the treatment of complement mediated conditions MUNICH, April 17, 2023 /PRNewswire/ -- Complement...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Complement Therapeutics
Sign Up For FreeTo access detailed company insights
Complement Therapeutics is a biotechnology company focused on developing innovative treatments based on insights from the Complement System, particularly for age-related macular degeneration and other complement-related diseases. The company leverages its world-leading expertise and patented research to create novel therapeutic approaches, includin... Read More
